Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Washington University School of Medicine
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18
Karnofsky Performance Status of ≥ 60
Pathologically confirmed IHC or HCC. (Pathology not required for HCC if the lesion enhances typically on MRI and the patient is evaluated by liver transplant surgery team and thought to have HCC.)
4 or less separate intrahepatic lesions, with at least one lesion that is able to be followed by EASL Criteria.
Local surgical resection is not possible due to tumor or patient factors
Limited metastatic disease is allowed if the volume of metastatic disease does not exceed the volume of primary disease.
Prior TACE allowed if stopped/completed at least 2 weeks prior to enrollment
Prior chemotherapy except Sorafenib allowed if stopped/completed at least 2 weeks prior to enrollment
Prior Sorafenib allowed if stopped/completed at least seven days prior to enrollment.
Able to provide signed informed consent
You may not be if
Childs-Pugh score 9 or more
ALT or AST ≥ 6 x upper limit of normal
Prior history of abdominal irradiation
Women who are pregnant or nursing
Scheduled to undergo chemotherapy except Sorafenib at the time when radiation therapy will be given, or for up to 4 weeks after completion of radiation therapy.
Scheduled to undergo Sorafenib within seven days of when radiation therapy will be delivered, or for up to 2 weeks after completion of radiation therapy.
Undergone prior radiation therapy to the abdomen.
Clareo Health | Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma
